Latest Revenue Growth News

Appen Limited delivered a robust Q4 FY25, driven by explosive growth in its China segment and strong gains in generative AI projects globally, boosting revenue and profitability significantly.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.

Urbanise.com Limited reported a 22% revenue increase in Q2 FY2026, driven by its strategic partnership with National Australia Bank and ongoing development of its Data and Payments Integration Services platform. Despite short-term cash outflows, the company targets positive operating cash flow by FY2027.

6K Additive reported a strong finish to 2025 with a 25% revenue jump in Q4 and secured $31.4 million in IPO proceeds to fuel a fivefold production expansion. The company also landed a $27.4 million US government-backed loan, positioning it for accelerated growth in the additive manufacturing sector.

BetMakers Technology Group reports a robust Q2 FY26 with 14.1% revenue growth and a $2.7 million positive Adjusted EBITDA, underpinned by key partnerships and margin expansion.

Image Resources NL reported a strong finish to 2025 with record heavy mineral concentrate production and sales, alongside promising developments in its gold exploration and synthetic rutile innovation.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.